iTeos Therapeutics: Combating cancer using immunotherapy against novel target combinations




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: iTeos Therapeutics: Combating cancer using immunotherapy against novel target combinations
Released on: March 15, 2017. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    iTeos Therapeutics is a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL).
  • Summary
  • Transcript
  • Participants
  • Company
iTeos Therapeutics is a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL). Focused on expanding the benefits of immunotherapy for cancer patients, the company is developing a proprietary pipeline targeting A2A, immune checkpoints and non-inflamed tumors. Adrian Dawkes speaks to Christophe Queva, CEO of iTeos Therapeutics.
iTeos Therapeutics is a spin-off from the Ludwig Cancer Research (LICR) and de Duve Institute (UCL). Focused on expanding the benefits of immunotherapy for cancer patients, the company is developing a proprietary pipeline targeting A2A, immune checkpoints and non-inflamed tumors. Adrian Dawkes speaks to Christophe Queva, CEO of iTeos Therapeutics.
Christophe Queva
iTeos Therapeutics